Onswik is approved to improve glycemic control in adults with Type 2 diabetes and will be available in the United States in the coming months in two concentrations. No information is available on the list price.
News|Articles|September 1, 2008
Drug Watch: Agents in late-stage development for the treatment of types 1 and 2 diabetes mellitus (September 2008) (PDF)
Drug Watch: Agents in late-stage development for the treatment of types 1 and 2 diabetes mellitus (September 2008)
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
UCLA research suggests that GLP-1 therapies may protect bone health in Type 2 diabetes patients.
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
In both mice and human cells, a small molecule selectively blocked the activity of MAP4K4, a protein involved in several major biological pathways.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Texas A&M researchers discover promising therapy for fatty liver disease
2
Survey identifies what doctors and patients want from support programs
3
FDA approves Lilly’s Onswik, the second once-weekly insulin
4
Low birth volume, finances tied to hospital obstetric unit closures
5